Evidence map›Paper›PMID 34461273›Full record

ArticleAnaerobe2021

Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains.

Masaad Saeed Almutairi, Anne J Gonzales-Luna, Faris S Alnezary, Saad B Fallatah, M Jahangir Alam, Khurshida Begum, Kevin W Garey

Open access · greenAbstract read
In one paragraph

Article in Anaerobe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Phenotypic analysis of variousApplied and environmental microbiology · 2025
    Article
  3. Phenotypic analysis of variousbioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Masaad Saeed AlmutairiDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Anne J Gonzales-LunaDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. Electronic address: ajgonz23@Central.UH.EDU.
Faris S AlnezaryDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
Saad B FallatahDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA; Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
M Jahangir AlamDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Khurshida BegumDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Kevin W GareyDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. Electronic address: kgarey@uh.edu.
University of Houston · USTaibah University · SAQassim University · SA

Funding

Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0M
Decoding Antibiotic-induced Susceptibility to Clostridium difficile InfectionU01AI124290 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BRITTON, ROBERT A, GAREY, KEVIN W · 2016 to 2020
$7.9M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS U01 AI124290
6 · The paper itself

Abstract

backgroundAlthough Clostridioides difficile surveillance often identifies emerging strains, clinical outcome evaluations are rarely performed. Ribotype (RT) 106 is a commonly isolated C. difficile strain worldwide; however, studies investigating RT 106 clinical outcomes are limited. The purpose of this study was to investigate clinical outcomes of RT 106 infections compared with two other endemic strains of varying virulence.

methodsThis multicenter study evaluated adults hospitalized with C. difficile infection (CDI). C. difficile samples underwent PCR ribotyping and patients infected with RT 106 were compared to patients infected with a known hypervirulent strain (RT 027) and a strain associated with less virulence (RT 014-020). Electronic medical records were reviewed by blinded investigators to assess the primary outcome of poor clinical outcome (composite of initial clinical failure, discharge to a higher level of care, 90-day CDI recurrence, and CDI-contributable mortality).

resultsA total of 396 patients with CDI were identified (RT 106, 32.3%; RT 027, 29.3%; RT 014-020, 38.3%). Patients infected with RT 014-020 less often experienced a poor clinical outcome (40%) compared with RT 106 (56%) and RT 027 (65%) infection (P < 0.0001). After controlling for covariates and using RT 014-020 as a comparator, patients infected with RT 106 (OR, 2.25; 95% CI, 1.36-3.73) or RT 027 (OR, 2.56; 95% CI, 1.52-4.31) had higher odds of poor clinical outcome. Using RT 027 as the comparator, only RT 014-020 was associated with lower odds of poor clinical outcome (OR, 0.42; 95% CI, 0.27-0.65).

conclusionThis study demonstrated that the emergent C. difficile RT 106 was associated with increased rates of poor clinical outcomes compared to RT 014-020 and comparable poor clinical outcomes to RT 027. These findings can help to better understand the clinical significance of this and future emerging ribotypes.

Indexed as

GenotypeAgedAged, 80 and overBacterial ToxinsClostridioides difficileClostridium InfectionsCross InfectionFemaleHospitalizationHospital MortalityHumansMaleMiddle AgedPrognosisRetrospective StudiesRibotypingBacterial ToxinsClostridium difficileRibotype 014–020Ribotype 027SurveillanceTyping

Identifiers

PMID34461273
PMCPMC8678208
OpenAlexW3198117253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.